Product
HPN424 Prime Step IV 36 ng/kg Target
1 clinical trial
1 indication
Indication
Prostate CancerClinical trial
A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients With Advanced Prostate Cancer Refractory to Androgen TherapyStatus: Terminated, Estimated PCD: 2023-02-27